Search research articles
Contact Us
Filters
Showing results (11-20 of 36) with videos related to
Page
of 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2019
Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [<sup>18</sup>F]FLT and [<sup>18</sup>F]ISO-1 PET/CT
Azadeh Elmi, Mehran Makvandi, Chi-Chang Weng, et al.
Nuclear Medicine and Biology
|
December 26, 2015
The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic
Mehran Makvandi, Brian P Lieberman, Ben LeGeyt, et al.
Journal of Medicinal Chemistry
|
June 2, 2018
Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity
Sean W Reilly, Laura N Puentes, Khadija Wilson, et al.
Biochemical and Biophysical Research Communications
|
June 22, 2019
Correlation analysis of [<sup>18</sup>F]ROStrace using ex vivo autoradiography and dihydroethidium fluorescent imaging in lipopolysaccharide-treated animals
Chi-Chang Weng, Sean Carlin, Catherine Hou, et al.
Scientific Reports
|
November 17, 2018
Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex
Aladdin Riad, Chenbo Zeng, Chi-Chang Weng, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 3, 2019
PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma
Hwan Lee, Aladdin Riad, Paul Martorano, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
January 25, 2017
PARP-1 Expression Quantified by [<sup>18</sup>F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy
Samuel Sander Effron, Mehran Makvandi, Lilie Lin, et al.
Cell Death Discovery
|
February 1, 2019
TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death
Chenbo Zeng, Chi-Chang Weng, Mark E Schneider, et al.
Biochemical and Biophysical Research Communications
|
October 11, 2015
The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer
Mehran Makvandi, Estifanos D Tilahun, Brian P Lieberman, et al.
EJNMMI Research
|
November 23, 2016
Improved safety and efficacy of <sup>213</sup>Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine
Ho Sze Chan, Mark W Konijnenberg, Tamara Daniels, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 36) with videos related to
Sort By:
Page
of 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2019
Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [<sup>18</sup>F]FLT and [<sup>18</sup>F]ISO-1 PET/CT
Azadeh Elmi, Mehran Makvandi, Chi-Chang Weng, et al.
Nuclear Medicine and Biology
|
December 26, 2015
The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic
Mehran Makvandi, Brian P Lieberman, Ben LeGeyt, et al.
Journal of Medicinal Chemistry
|
June 2, 2018
Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity
Sean W Reilly, Laura N Puentes, Khadija Wilson, et al.
Biochemical and Biophysical Research Communications
|
June 22, 2019
Correlation analysis of [<sup>18</sup>F]ROStrace using ex vivo autoradiography and dihydroethidium fluorescent imaging in lipopolysaccharide-treated animals
Chi-Chang Weng, Sean Carlin, Catherine Hou, et al.
Scientific Reports
|
November 17, 2018
Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex
Aladdin Riad, Chenbo Zeng, Chi-Chang Weng, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 3, 2019
PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma
Hwan Lee, Aladdin Riad, Paul Martorano, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
January 25, 2017
PARP-1 Expression Quantified by [<sup>18</sup>F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy
Samuel Sander Effron, Mehran Makvandi, Lilie Lin, et al.
Cell Death Discovery
|
February 1, 2019
TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death
Chenbo Zeng, Chi-Chang Weng, Mark E Schneider, et al.
Biochemical and Biophysical Research Communications
|
October 11, 2015
The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer
Mehran Makvandi, Estifanos D Tilahun, Brian P Lieberman, et al.
EJNMMI Research
|
November 23, 2016
Improved safety and efficacy of <sup>213</sup>Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine
Ho Sze Chan, Mark W Konijnenberg, Tamara Daniels, et al.
Page
of 4